CareDx (CDNA) Stock Price, News & Analysis

Company Overview

CareDx, Inc. is a precision medicine company focused on organ transplantation. It develops and provides diagnostic tests and related services to help clinicians assess transplant recipients and monitor their health over time.

Its offerings include AlloSure, a donor-derived cell-free DNA test used to help monitor for organ rejection, and AlloMap, a gene-expression test used in heart transplant care. CareDx also provides histocompatibility testing, clinical tools, and services designed to support patients and transplant care teams.

The company traces its roots to XDx, founded in 1998, and adopted the CareDx name in 2010. It serves transplant centers and patients in the United States and other markets.

Key Stats

• Today's Range: $80.18 to $84.10
• 50-Day Range: $48.97 to $88.47
• 52-Week Range: $15.15 to $90.87
• Volume: 770,767 shs
• Average Volume: 984,027 shs
• Market Capitalization: $4.26 billion
• P/E Ratio: 33.93
• Dividend Yield: N/A
• Price Target: $70.33
• Consensus Rating: Moderate Buy

CareDx Stock Analysis - MarketRank™

CareDx scored higher than 25% of companies evaluated by MarketBeat, and ranked 784th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

CareDx has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 4 buy ratings, 4 hold ratings, and no sell ratings.

Downside Risk

CareDx has a consensus price target of $70.33, representing about 14.1% downside from its current price of $81.91.

Amount of Analyst Coverage

CareDx has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: -10.10%

Earnings Growth

Earnings for CareDx are expected to decrease by -10.10% in the coming year, from $0.99 to $0.89 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of CareDx is 34.28, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 26.52.

Price to Earnings Ratio vs. Sector

The P/E ratio of CareDx is 34.28, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.20.

Price to Book Value per Share Ratio

CareDx has a P/B Ratio of 9.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

14.02% of the float of CareDx has been sold short.

Short Interest Ratio / Days to Cover

CareDx has a short interest ratio ("days to cover") of 5.28.

Change versus previous month

Short interest in CareDx has recently increased by 7.03%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CareDx does not currently pay a dividend.

Dividend Growth

CareDx does not have a long track record of dividend growth.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 0.63

News Sentiment

CareDx has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 12 news articles for CareDx this week, compared to 4 articles on an average week.

Search Interest

21 people have searched for CDNA on MarketBeat in the last 30 days. This is an increase of 163% compared to the previous 30 days.

MarketBeat Follows

6 people have added CareDx to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, CareDx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,821,805.00 in company stock.

Percentage Held by Insiders

2.40% of the stock of CareDx is held by insiders.

Percentage Held by Institutions

CareDx has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 10/29/2026
• Today: 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:CDNA
• CIK: 1217234
• Web: www.caredx.com
• Phone: (415) 287-2300
• Fax: 415-287-2450
• Employees: 765
• Year Founded: 2000

Price Target and Rating

• Average Price Target for CareDx: $70.33
• High Price Target: $100.00
• Low Price Target: $21.00
• Potential Upside/Downside: -13.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.39
• Trailing P/E Ratio: 33.93
• Forward P/E Ratio: 91.12
• P/E Growth: N/A
• Net Income: -$21.35 million
• Net Margins: 25.86%
• Pretax Margin: 24.98%
• Return on Equity: 9.74%
• Return on Assets: 7.35%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.31
• Quick Ratio: 2.25

Sales & Book Value

• Annual Sales: $497.40 million
• Price / Sales: 8.57
• Cash Flow: $0.01 per share
• Price / Cash Flow: 12,960.97
• Book Value: $8.90 per share
• Price / Book: 9.11

Miscellaneous

• Outstanding Shares: 52,543,000
• Free Float: 51,282,000
• Market Cap: $4.26 billion
• Optionable: Optionable
• Beta: 2.50